Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study outlines the safety of the autologous SVF cells injection in the hands of patients with SSc. Preliminary assessments at 6 months will suggest potential efficacy needing confirmation in a randomised placebo-controlled trial on a larger population
In patients with systemic sclerosis(scleroderma, SSc), impaired hand function greatly contributes to disability and reduced quality of life, and is insufficiently relived by currently available therapies. Adipose tissue-derived stromal vascular fraction (SVF) is increasingly recognized as an easily accessible source of regenerative cells with therapeutic potential in ischaemic or autoimmune disease. The investigators aimed to measure for the first time the safety, tolerability, and potential efficacy of autologous SVF cells local injections in patients with SSc with hand disability.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SVF injection | Experimental | SVF was obtained from lipoaspirates, using an automated processing system, and subsequently injected into the subcutaneous tissue of each finger in contact with neurovascular pedicles |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SVF injection | Procedure | SVF is increasingly recognised as an easily accessible source of regenerative cells with therapeutic potential in ischaemic or autoimmune disease. We aimed to measure for the first time the safety, tolerability and potential efficacy of autologous SVF cells local injections in patients with systemic sclerosis |
| Measure | Description | Time Frame |
|---|---|---|
| Raynaud's Condition Scale | The severity of Raynaud's phenomenon was assessed using the Raynaud's condition scale (ranging 0 to 10, with higher scores representing more severe Raynaud's phenomenon) | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
| Hand Visual Analogue Scale | Hand pain was assessed using the Hand visual analogue scale (ranging 0 to 10, with higher scores representing more severe pain) | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
| Colchin Hand Function Scale | The Colchin hand function scale (CHFS, ranging 0 to 90, with higher scores representing more deteriorated hand function) scores | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
| Kapandji Score (Ranging 0 to 10) - Dominant Hand | Kapandji score (ranging 0 to 10) is validated measures in past studies as outcomes for hand disability. The Kapandji score is a tool useful for assessing the opposition of the thumb, based on where on their hand the patient is able to touch with the tip of their thumb. A score of 0 indicates no opposition, a score of 10 indicates maximal opposition. | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
| Kapandji Score (Non-dominant Hand) | Kapandji score (ranging 0 to 10) is validated measures in past studies as outcomes for hand disability. The Kapandji score is a tool useful for assessing the opposition of the thumb, based on where on their hand the patient is able to touch with the tip of their thumb. A score of 0 indicates no opposition, a score of 10 indicates maximal opposition. | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
| Disease-related QOL (Quality of Life) : EuroQol-5 Dimensions Time Trade-off (EQ-5D TTO) |
| Measure | Description | Time Frame |
|---|---|---|
| Changes of Nailfold Capillary Microscopic Findings (Irregularly Enlarged Capillaries) | In order to assess the severity of microangiopathies in both fingers, a semiquantitative scoring system for nailfold capillary microscopic findings was adopted. A total of six parameters (irregularly enlarged capillaries, giant capillaries, hemorrhages, loss of capillaries, disorganization of the vascular array and capillary ramifications) were measured using the semiquantitative manner on the scale ranging 0 to 3, indicating more severe as scores were higher. Each parameter was scored for four fingers of both hands, except thumbs, and the median score value of each parameter in both hands was finally presented. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Suk-Ho Moon, MD, PhD | Seoul St. Mary's Hospital | Study Director |
| Seung-Ki Kwok | Seoul St. Mary's Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea | Seoul | South Korea |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32961802 | Derived | Park Y, Lee YJ, Koh JH, Lee J, Min HK, Kim MY, Kim KJ, Lee SJ, Rhie JW, Kim WU, Park SH, Moon SH, Kwok SK. Clinical Efficacy and Safety of Injection of Stromal Vascular Fraction Derived from Autologous Adipose Tissues in Systemic Sclerosis Patients with Hand Disability: A Proof-Of-Concept Trial. J Clin Med. 2020 Sep 19;9(9):3023. doi: 10.3390/jcm9093023. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection.
Between July 2018 and December 2019, a total of twenty subjects were enrolled in this single center, open label, phase I trial.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | SVF Injection Group | Participants received SVF treatment, and were fully followed-up for the whole scheduled period for clinical assessment. SVF extraction and injection were performed in outpatient setting within at least 1 month after baseline evaluation. All patients were regulary assessed for intervention-related adverse events and clinical efficacies at 2 weeks (2W), 6 weeks (6W), 12 weeks (12W) and 24 weeks (24W) after their procedure. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | SVF Injection | SVF was obtained from lipoaspirates, using an automated processing system, and subsequently injected into the subcutaneous tissue of each finger in contact with neurovascular pedicles SVF injection: SVF is increasingly recognised as an easily accessible source of regenerative cells with therapeutic potential in ischaemic or autoimmune disease. We aimed to measure for the first time the safety, tolerability and potential efficacy of autologous SVF cells local injections in patients with systemic sclerosis |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Raynaud's Condition Scale | The severity of Raynaud's phenomenon was assessed using the Raynaud's condition scale (ranging 0 to 10, with higher scores representing more severe Raynaud's phenomenon) | Posted | Median | Inter-Quartile Range | score on a scale | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
|
Up to 24 weeks
No serious adverse events occurred throughout study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | SVF Injection Group | Participants received SVF treatment. All patients were regulary assessed at 2 weeks (2W), 6 weeks (6W), 12 weeks (12W) and 24 weeks (24W) after their procedure. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Transient paresthesia in liposuction lesions | Injury, poisoning and procedural complications | MedDRA (10.0) | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Suk-Ho Moon | Department of Plastic Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea | 821090803527 | nasuko@catholic.ac.kr |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | May 28, 2020 | Oct 3, 2020 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D012595 | Scleroderma, Systemic |
| ID | Term |
|---|---|
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Systemic sclerosis patients with hand disability, planning 24 weeks of follow-up period Autologous adipose tissue-derived stromal vascular fraction(SVF) injected into the subcutaneous tissue of each finger in contact with neurovascular pedicles.
Not provided
Not provided
Not provided
Not provided
|
Disease-related QOL (quality of life) was measured by EuroQol-5 dimensions time trade-off (EQ-5D TTO, ranging 0 to 1, with higher values representing better QOL) values |
| Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
| Disease-related QOL (Quality of Life) : EuroQol Visual Analog Scale (EQ VAS) | Disease-related QOL (quality of life) : EuroQol visual analog scale (EQ VAS, ranging 0 to 100, with higher scores representing better QOL) | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
| Disease-related QOL (Quality of Life) : Health Assessment Questionnaire (HAQ) | Disease-related QOL (quality of life) : health assessment questionnaire (HAQ, ranging 0 to 3, with higher scores meaning lower QOL) | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
| The Degree of Hand Edema (Right) | The finger circumferences of the second to the fifth fingers measured in the middle portion of each proximal phalanx were used to assess the degree of hand edema | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
| The Degree of Hand Edema (Left) | The finger circumferences of the second to the fifth fingers measured in the middle portion of each proximal phalanx were used to assess the degree of hand edema | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
| Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
| Changes of Nailfold Capillary Microscopic Findings (Giant Capillaries) | In order to assess the severity of microangiopathies in both fingers, a semiquantitative scoring system for nailfold capillary microscopic findings was adopted. A total of six parameters (irregularly enlarged capillaries, giant capillaries, hemorrhages, loss of capillaries, disorganization of the vascular array and capillary ramifications) were measured using the semiquantitative manner on the scale ranging 0 to 3, indicating more severe as scores were higher. Each parameter was scored for four fingers of both hands, except thumbs, and the median score value of each parameter in both hands was finally presented. | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
| Changes of Nailfold Capillary Microscopic Findings (Hemorrhages) | In order to assess the severity of microangiopathies in both fingers, a semiquantitative scoring system for nailfold capillary microscopic findings was adopted. A total of six parameters (irregularly enlarged capillaries, giant capillaries, hemorrhages, loss of capillaries, disorganization of the vascular array and capillary ramifications) were measured using the semiquantitative manner on the scale ranging 0 to 3, indicating more severe as scores were higher. Each parameter was scored for four fingers of both hands, except thumbs, and the median score value of each parameter in both hands was finally presented. | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
| Changes of Nailfold Capillary Microscopic Findings (Loss of Capillaries) | In order to assess the severity of microangiopathies in both fingers, a semiquantitative scoring system for nailfold capillary microscopic findings was adopted. A total of six parameters (irregularly enlarged capillaries, giant capillaries, hemorrhages, loss of capillaries, disorganization of the vascular array and capillary ramifications) were measured using the semiquantitative manner on the scale ranging 0 to 3, indicating more severe as scores were higher. Each parameter was scored for four fingers of both hands, except thumbs, and the median score value of each parameter in both hands was finally presented. | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
| Changes of Nailfold Capillary Microscopic Findings (Disorganization of the Vascular Array) | In order to assess the severity of microangiopathies in both fingers, a semiquantitative scoring system for nailfold capillary microscopic findings was adopted. A total of six parameters (irregularly enlarged capillaries, giant capillaries, hemorrhages, loss of capillaries, disorganization of the vascular array and capillary ramifications) were measured using the semiquantitative manner on the scale ranging 0 to 3, indicating more severe as scores were higher. Each parameter was scored for four fingers of both hands, except thumbs, and the median score value of each parameter in both hands was finally presented. | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
| Changes of Nailfold Capillary Microscopic Findings (Capillary Ramifications) | In order to assess the severity of microangiopathies in both fingers, a semiquantitative scoring system for nailfold capillary microscopic findings was adopted. A total of six parameters (irregularly enlarged capillaries, giant capillaries, hemorrhages, loss of capillaries, disorganization of the vascular array and capillary ramifications) were measured using the semiquantitative manner on the scale ranging 0 to 3, indicating more severe as scores were higher. Each parameter was scored for four fingers of both hands, except thumbs, and the median score value of each parameter in both hands was finally presented. | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
| Median |
| Inter-Quartile Range |
| years |
|
| Sex: Female, Male | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Body mass index (BMI) kg/m2 | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Median | Inter-Quartile Range | kg/m2 |
|
| Disease duration (years) | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Median | Inter-Quartile Range | years |
|
| Reynaud's phenomenon duration | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Median | Inter-Quartile Range | years |
|
| Smoking history (Current or ex-) | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Interstitial lung disease | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Types of cutaneous manisfetations (diffuse or limited) | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Hand dominance (right) | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Pulmonary hypertension | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| History of renal crisis | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Diabetes mellitus | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Hypertension | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Osteoporosis | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Medication status (calcium channel blocker) | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Medication status (prostacyclin) | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Medication status (Aloprostadil) | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Medication status (Endothelial receptor antagonist)) | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Medication status (Azathioprine) | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Medication status (Glucocorticoid) | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Medication status (Methotrexate) | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Anti-nuclear antibody | Antinuclear autoantibodies are present in more than 90% of patients with systemic sclerosis (SSc). The presence of antinuclear antibodies is a central feature of systemic sclerosis. | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Anti-centromere antibody | Anti-centromere antibodies are autoantibodies specific to centromere function. They occur in some autoimmune diseases, freqently in limited systemic scleroderma. | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Anti-Scl70 antibody | Anti-Scl-70 autoantibodies are found in 20~35% of patients with systemic sclerosis, mainly in those with the diffuse form of the disease. | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Anti-Ro/SSA antibody | Anti-Ro/SSA antibodies are anti-nuclear autoantibodies that are associated with many autoimmune diseases. | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Anti-U1 RNP antibody | Anti-U1 RNP antibody is generally known to be a serological marker for mixed connective tissue disease, but can be detected also in patients with definite systemic sclerosis. | Among the initially enrolled patients, one patient refused further procedures after baseline evaluation, while another patient dropped out due to complications during local anesthesia right before SVF injection (one patient dropout due to dizziness after lidocaine injection where the prepared SVF was discarded). | Count of Participants | Participants |
|
| Units | Counts |
|---|
| Participants |
|
|
|
| Primary | Hand Visual Analogue Scale | Hand pain was assessed using the Hand visual analogue scale (ranging 0 to 10, with higher scores representing more severe pain) | Posted | Median | Inter-Quartile Range | score on a scale | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
|
|
|
|
| Primary | Colchin Hand Function Scale | The Colchin hand function scale (CHFS, ranging 0 to 90, with higher scores representing more deteriorated hand function) scores | Posted | Median | Inter-Quartile Range | score on a scale | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
|
|
|
|
| Primary | Kapandji Score (Ranging 0 to 10) - Dominant Hand | Kapandji score (ranging 0 to 10) is validated measures in past studies as outcomes for hand disability. The Kapandji score is a tool useful for assessing the opposition of the thumb, based on where on their hand the patient is able to touch with the tip of their thumb. A score of 0 indicates no opposition, a score of 10 indicates maximal opposition. | Posted | Median | Inter-Quartile Range | score on a scale | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
|
|
|
|
| Primary | Kapandji Score (Non-dominant Hand) | Kapandji score (ranging 0 to 10) is validated measures in past studies as outcomes for hand disability. The Kapandji score is a tool useful for assessing the opposition of the thumb, based on where on their hand the patient is able to touch with the tip of their thumb. A score of 0 indicates no opposition, a score of 10 indicates maximal opposition. | Posted | Median | Inter-Quartile Range | score on a scale | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
|
|
|
|
| Primary | Disease-related QOL (Quality of Life) : EuroQol-5 Dimensions Time Trade-off (EQ-5D TTO) | Disease-related QOL (quality of life) was measured by EuroQol-5 dimensions time trade-off (EQ-5D TTO, ranging 0 to 1, with higher values representing better QOL) values | Posted | Median | Inter-Quartile Range | score on a scale | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
|
|
|
|
| Primary | Disease-related QOL (Quality of Life) : EuroQol Visual Analog Scale (EQ VAS) | Disease-related QOL (quality of life) : EuroQol visual analog scale (EQ VAS, ranging 0 to 100, with higher scores representing better QOL) | Posted | Median | Inter-Quartile Range | score on a scale | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
|
|
|
|
| Primary | Disease-related QOL (Quality of Life) : Health Assessment Questionnaire (HAQ) | Disease-related QOL (quality of life) : health assessment questionnaire (HAQ, ranging 0 to 3, with higher scores meaning lower QOL) | Posted | Median | Inter-Quartile Range | score on a scale | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
|
|
|
|
| Primary | The Degree of Hand Edema (Right) | The finger circumferences of the second to the fifth fingers measured in the middle portion of each proximal phalanx were used to assess the degree of hand edema | Posted | Median | Inter-Quartile Range | cm | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
|
|
|
|
| Primary | The Degree of Hand Edema (Left) | The finger circumferences of the second to the fifth fingers measured in the middle portion of each proximal phalanx were used to assess the degree of hand edema | Posted | Median | Inter-Quartile Range | cm | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
|
|
|
|
| Secondary | Changes of Nailfold Capillary Microscopic Findings (Irregularly Enlarged Capillaries) | In order to assess the severity of microangiopathies in both fingers, a semiquantitative scoring system for nailfold capillary microscopic findings was adopted. A total of six parameters (irregularly enlarged capillaries, giant capillaries, hemorrhages, loss of capillaries, disorganization of the vascular array and capillary ramifications) were measured using the semiquantitative manner on the scale ranging 0 to 3, indicating more severe as scores were higher. Each parameter was scored for four fingers of both hands, except thumbs, and the median score value of each parameter in both hands was finally presented. | Posted | Median | Inter-Quartile Range | score on a scale | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
|
|
|
|
| Secondary | Changes of Nailfold Capillary Microscopic Findings (Giant Capillaries) | In order to assess the severity of microangiopathies in both fingers, a semiquantitative scoring system for nailfold capillary microscopic findings was adopted. A total of six parameters (irregularly enlarged capillaries, giant capillaries, hemorrhages, loss of capillaries, disorganization of the vascular array and capillary ramifications) were measured using the semiquantitative manner on the scale ranging 0 to 3, indicating more severe as scores were higher. Each parameter was scored for four fingers of both hands, except thumbs, and the median score value of each parameter in both hands was finally presented. | Posted | Median | Inter-Quartile Range | score on a scale | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
|
|
|
|
| Secondary | Changes of Nailfold Capillary Microscopic Findings (Hemorrhages) | In order to assess the severity of microangiopathies in both fingers, a semiquantitative scoring system for nailfold capillary microscopic findings was adopted. A total of six parameters (irregularly enlarged capillaries, giant capillaries, hemorrhages, loss of capillaries, disorganization of the vascular array and capillary ramifications) were measured using the semiquantitative manner on the scale ranging 0 to 3, indicating more severe as scores were higher. Each parameter was scored for four fingers of both hands, except thumbs, and the median score value of each parameter in both hands was finally presented. | Posted | Median | Inter-Quartile Range | score on a scale | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
|
|
|
|
| Secondary | Changes of Nailfold Capillary Microscopic Findings (Loss of Capillaries) | In order to assess the severity of microangiopathies in both fingers, a semiquantitative scoring system for nailfold capillary microscopic findings was adopted. A total of six parameters (irregularly enlarged capillaries, giant capillaries, hemorrhages, loss of capillaries, disorganization of the vascular array and capillary ramifications) were measured using the semiquantitative manner on the scale ranging 0 to 3, indicating more severe as scores were higher. Each parameter was scored for four fingers of both hands, except thumbs, and the median score value of each parameter in both hands was finally presented. | Posted | Median | Inter-Quartile Range | score on a scale | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
|
|
|
|
| Secondary | Changes of Nailfold Capillary Microscopic Findings (Disorganization of the Vascular Array) | In order to assess the severity of microangiopathies in both fingers, a semiquantitative scoring system for nailfold capillary microscopic findings was adopted. A total of six parameters (irregularly enlarged capillaries, giant capillaries, hemorrhages, loss of capillaries, disorganization of the vascular array and capillary ramifications) were measured using the semiquantitative manner on the scale ranging 0 to 3, indicating more severe as scores were higher. Each parameter was scored for four fingers of both hands, except thumbs, and the median score value of each parameter in both hands was finally presented. | Posted | Median | Inter-Quartile Range | score on a scale | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
|
|
|
|
| Secondary | Changes of Nailfold Capillary Microscopic Findings (Capillary Ramifications) | In order to assess the severity of microangiopathies in both fingers, a semiquantitative scoring system for nailfold capillary microscopic findings was adopted. A total of six parameters (irregularly enlarged capillaries, giant capillaries, hemorrhages, loss of capillaries, disorganization of the vascular array and capillary ramifications) were measured using the semiquantitative manner on the scale ranging 0 to 3, indicating more severe as scores were higher. Each parameter was scored for four fingers of both hands, except thumbs, and the median score value of each parameter in both hands was finally presented. | Posted | Median | Inter-Quartile Range | score on a scale | Baseline, 2 weeks, 6 weeks, 12 weeks, 24 weeks |
|
|
|
|
| 0 |
| 20 |
| 0 |
| 20 |
| 5 |
| 20 |
| Dizziness after lidocaine injection | Injury, poisoning and procedural complications | MedDRA (10.0) | Non-systematic Assessment |
|
| Transient pallor in finger after injection | Injury, poisoning and procedural complications | MedDRA (10.0) | Non-systematic Assessment |
|
Not provided
Not provided
| Title | Measurements |
|---|---|
|
| 12 weeks |
|
| 24 weeks |
|
| Title | Measurements |
|---|---|
|
| 12 weeks |
|
| 24 weeks |
|
| Title | Measurements |
|---|---|
|
| 12 weeks |
|
| 24 weeks |
|
| Title | Measurements |
|---|---|
|
| 12 weeks |
|
| 24 weeks |
|
| Title | Measurements |
|---|---|
|
| 12 weeks |
|
| 24 weeks |
|
| Title | Measurements |
|---|---|
|
| 12 weeks |
|
| 24 weeks |
|
| Title | Measurements |
|---|---|
|
| 12 weeks |
|
| 24 weeks |
|
| Title | Measurements |
|---|---|
|
| 12 weeks |
|
| 24 weeks |
|
| Title | Measurements |
|---|---|
|
| 12 weeks |
|
| 24 weeks |
|
| Title | Measurements |
|---|---|
|
| 12 weeks |
|
| 24 weeks |
|
| Title | Measurements |
|---|---|
|
| 12 weeks |
|
| 24 weeks |
|
| Title | Measurements |
|---|---|
|
| 12 weeks |
|
| 24 weeks |
|
| Title | Measurements |
|---|---|
|
| 12 weeks |
|
| 24 weeks |
|
| Title | Measurements |
|---|---|
|
| 12 weeks |
|
| 24 weeks |
|
| Title | Measurements |
|---|---|
|
| 12 weeks |
|
| 24 weeks |
|